(ALIGN) - A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function

  • Ryan, Jessica (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date7/05/21 → 6/05/26

Keywords

  • clinical trial
  • treatment safety
  • treatment efficacy
  • renal function
  • phase 3 study

Clinical Trial Phase

  • Phase III (a & b)